Invasive Aspergillosis: A New Important Risk Factor On Short and Long-Term Survival of AML Patients.
M. Michallet(Hospices Civils de Lyon), Philippe Vanhems(Université Claude Bernard Lyon 1), Marie-Christine Nicoll(Hôpital Edouard Herriot), Emmanuelle Nicolas‐Virelizier(Hôpital Edouard Herriot), Samira Kraghel(Hospices Civils de Lyon), Giovanna Cannas(Hôpital Edouard Herriot), Roberto Crocchiolo(Istituti di Ricovero e Cura a Carattere Scientifico), Fiorenza Barraco(Hôpital Lyon Sud), Youcef Chelghoum(Hôpital Edouard Herriot), Mohamed El Hamri(Hospices Civils de Lyon), Samia Madene(Hôpital Edouard Herriot), Florence Persat(Université Claude Bernard Lyon 1), Xavier Thomas(Hôpital Lyon Sud), Frédérique de Monbrison(Hôpital de la Croix-Rousse), Franck E. Nicolini(Inserm), Najeeb Fanari(Hôpital Edouard Herriot), Mohamad Sobh(Ottawa Hospital), Thomas Bénet(Lyon 1 Université), Anne‐Lise Bienvenu(Université Claude Bernard Lyon 1), Hélène Labussière(Hôpital Lyon Sud), Sophie Ducastelle(Hôpital Lyon Sud)
Cited by 1
Related Papers
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547